#USA #New York #Tenax Therapeutics #TENX #Stuart Rich

Overview of Tenax Therapeutics, Inc. Securities Class Action

On October 29, 2026, an alert was issued regarding a securities class action lawsuit involving Tenax Therapeutics, Inc. (NASDAQ: TENX), spotlighting its Chief Medical Officer, Stuart Rich, M.D. Investors who purchased Tenax securities between November 13, 2023, and August 7, 2026, may have grounds to recover their per-share losses due to alleged misleading statements related to the company's drug, TNX-103.

Background of the Case

The lawsuit arises from a sharp decline in the share price of Tenax following the company’s announcement that TNX-103 did not meet its primary endpoint during a Phase 3 clinical trial. Following this revelation on August 10, 2026, the stock price dropped approximately 89.77%, leading to concerns among investors over the drug's efficacy and the reliability of the clinical study results.

Allegations Against Dr. Stuart Rich

Dr. Rich is at the center of the class action due to his role in promoting TNX-103 and its clinical trial design. The complaint alleges that he made several misleading statements over various occasions, specifically on November 13 in the years 2023, 2024, and 2025. Each of these statements asserted the drug’s potential and the trial's confidence without reflecting the true outcomes.

• - 2023 Announcement: Dr. Rich announced that the IND for TNX-103 was cleared by the FDA and expressed optimism about the drug's consistency in drug concentration, implying enhanced efficacy.
• - 2024 Conference: During the Guggenheim Healthcare Innovation Conference, he characterized the trial's secondary endpoints as “realistic,” which further solidified investor confidence.
• - 2025 Virtual Call: He claimed that the trial was enriched with patients likely to respond positively, engendering trust among stakeholders.

However, the later data disclosed that patients on placebo outperformed those on TNX-103 significantly, casting doubt on Dr. Rich's statements and leading to the current legal action.

Legal Framework and Implications

The action is being pursued in the United States District Court for the Middle District of North Carolina, citing violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit centers on whether the assurances provided during various public interactions represent a fair and accurate portrayal of TNX-103's potential efficacy. Legal experts suggest that Dr. Rich's position as Chief Medical Officer gives weight to his statements, which could be pivotal in determining liability.

What Investors Should Know

Investors impacted by the drop in Tenax's stock price may wish to gather relevant brokerage records showing their purchase details to evaluate their eligibility for claims. SueWallSt, the firm handling this alert, provides no-cost assessments for affected investors. Whether investors still hold shares or sold at a loss, they may remain eligible to participate in any recovery efforts stemming from the class action.

Conclusion

As the situation unfolds, stakeholders are left to navigate the complexities of this lawsuit while considering their next steps. The deadline to become the lead plaintiff in this class action is set for December 28, 2026. Individuals potentially affected by this situation should remain informed and proactive in seeking legal recourse through the appropriate channels. Contact details for legal assistance have been provided for those who wish to pursue their claims further. This case exemplifies the critical nature of transparent communication in the pharmaceutical sector and the potential ramifications when assurances fall short of reality.